Mithra announces new agreement with GSP for development of an additional injectable


Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into a new agreement with Generic Speciality Pharma (GSP) for the development and supply of a sterile hormonal injectable product at Mithra CDMO1. Headquartered in Dublin, GSP is part of the Alter Pharma group, a Belgian pharmaceutical conglomerate focused on the development and manufacturing of niche generics, complex generics and high added value products.

This contract follows the first collaboration agreement concluded with GSP in 2017 for the development of four injectable products and confirms GSP's confidence in the technological know-how of Mithra CDMO in this complex field of activity. In addition to this major partnership, Mithra has been working on the development of a sterile injectable for the German group Midas Pharma since 2018. Thanks to its tripled production capacity and the acquisition of new equipment, Mithra CDMO is continuing to deploy its range of services, both in the Injectables division and for other complex therapeutic solutions.

François Fornieri, CEO Mithra Women’s Health, comments: “This new contract for our Injectables division confirms the excellent relationship established with GSP from the start of the development of their first four injectables at Mithra CDMO and demonstrates their confidence in our expertise and know-how. To meet the growing demand of our various partners, we have increased our production capacities and are constantly strengthening our R&D and production teams to offer a quality service throughout the development process.”


Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in Women’s Health, with a particular focus on contraception and menopause. Mithra’s goal is to develop new and improved products that meet women’s needs for better safety and convenience. Its three lead development candidates – a fifth generation oral contraceptive Estelle®, the first complete oral treatment for perimenopause PeriNesta™ and next-generation hormone therapy Donesta® - are built on Mithra’s unique native estrogen platform, E4 (Estetrol). Mithra also develops and manufactures complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its CDMO. Mithra was founded in 1999 as a spin-off from the University of Liège by François Fornieri and Prof. Dr. Jean-Michel Foidart. Mithra is headquartered in Liège, Belgium. Further information can be found at



Interested in a regular update of the Life Sciences and biotech sector in Flanders?